Dr. Jorge Castillo, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 457
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MA license 257257 · RI license LP00533
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- North Shore Medical Center - Salem, MA
- Cooley Dickinson Hospital Inc,the Northampton, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 457
- Services billed
- 936
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 271 | 205 |
| Established patient office or other outpatient visit, 40-54 minutes | 220 | 182 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 87 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 54 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 50 | 50 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 42 | 42 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | 17 |
| Hospital discharge day management, 30 minutes or less | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 167 |
| Imbruvica (ibrutinib) | 134 |
| Venclexta (venetoclax) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 18 payments worth $14,561 in total to this clinician.
| Beone Medicines USA, Inc. | $7,865 |
|---|---|
| AbbVie Inc. | $4,950 |
| Beone Medicines LTD. | $1,060 |
| Lantheus Medical Imaging, Inc. | $490 |
| Recordati_rare_diseases_inc. | $83.73 |
| Genmab U.S., Inc. | $59.99 |
| AstraZeneca Pharmaceuticals LP | $52.73 |
| Consulting Fee | $11,300 |
|---|---|
| Travel and Lodging | $2,679 |
| Food and Beverage | $583 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Apr 4, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $4,950 |
| Beone Medicines USA, Inc. Oct 14, 2025 | Consulting Fee | $4,800 |
| Beone Medicines LTD. Jun 19, 2025 | Consulting Fee | $610 |
| Beone Medicines USA, Inc. Nov 7, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $493 |
| Lantheus Medical Imaging, Inc. Jul 14, 2025 | Consulting Fee | $490 |
| Beone Medicines LTD. Jun 30, 2025 | Consulting Fee | $450 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 6, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $394 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Nov 7, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $493 |
| Beone Medicines USA, Inc. Nov 6, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 6, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $246 |
| Beone Medicines USA, Inc. Nov 6, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Cleveland, OH · in-kind | $200 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $449 |
| Beone Medicines USA, Inc. Nov 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Denver, CO · in-kind | $394 |
| Beone Medicines USA, Inc. Oct 14, 2025 | Consulting Fee | $4,800 |
| Lantheus Medical Imaging, Inc. Jul 14, 2025 | Consulting Fee | $490 |
| Beone Medicines LTD. Jun 30, 2025 | Consulting Fee | $450 |
| Beone Medicines LTD. Jun 19, 2025 | Consulting Fee | $610 |
| AbbVie Inc. Apr 4, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $4,950 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $1,246,678 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - Study name not reported
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.